{"id":326746,"date":"2026-10-26T14:16:33","date_gmt":"2026-10-26T08:46:33","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/eris-lifesciences-q2-results-fy27-pat-187-crore\/"},"modified":"2026-10-26T14:16:33","modified_gmt":"2026-10-26T08:46:33","slug":"eris-lifesciences-q2-results-fy27-pat-187-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/eris-lifesciences-q2-results-fy27-pat-187-crore\/","title":{"rendered":"Eris Lifesciences Q2 Results FY27: PAT Jumps 39.17% to Rs 187.14 Cr, Revenue Rs 892.37 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

Eris Lifesciences Q2 Results FY27 were declared on 26 October 2026, and the quarterly results show Consolidated revenue of Rs 892.37 Cr, up 12.61% YoY from Rs 792.41 Cr. Net profit rose 39.17% to Rs 187.14 Cr from Rs 134.47 Cr, while Operating Profit stood at Rs 309.35 Cr. This YoY growth in revenue and profit sets up the results analysis that follows.<\/p>\n<\/div>\n

Eris Lifesciences Ltd<\/a> (ERIS) Q2 Results FY27 announced on 26 October 2026, covering the company’s financial performance for the July to September quarter. Consolidated revenue of Rs 892.37 Cr and net profit (PAT) of Rs 187.14 Cr are the headline figures. The results date of 26 October 2026 marks when these consolidated results reached NSE and BSE, and Eris Lifesciences Q2 Results FY27 form the base for everything below.<\/p>\n

This results analysis of Eris Lifesciences Q2 Results walks through the financial highlights, the business drivers disclosed for the quarter, the outlook for FY27 and the risks worth tracking. The highlights table comes first, and the Univest Screener carries the same figures for readers who want to compare other companies.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n